Igeneon: Staying Close to Home

Igeneon's latest in-licensing rounds out its cancer immunotherapy pipeline with another compound its founders know well. IGN 301, an epithelial cancer vaccine, is the second of Igeneon's three clinical projects to originate from Novartis. Both were discovered under the guidance of Igeneon's founders, who have a combined 50 years' experience at the Swiss giant.